Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH”by Both Completer and ITT Analyses”at Week 96 in Phase 2
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH”by Both Completer and ITT Analyses”at Week 96 in Phase 2